Clinical Trials Browser

Esthesioneuroblastoma, Olfactory × Sarcoma × 1 year × Clear all

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Phase 2 Recruiting

40 enrolled

CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT04087902 2026-05-20

Long-Term Longitudinal QoL in Patients Undergoing EEA

Active not recruiting

400 enrolled

CNSEndocrineSarcoma

Chondrosarcoma, Chordoma, Craniopharyngioma, Encephalocele, Meningioma, Pituitary Neoplasms, Esthesioneuroblastoma, Olfactory, Central Nervous System Cysts

NCT07072143 2025-07-18

PARTNER

Recruiting

6,250 enrolled

CNSDermatologicGastrointestinalHead & NeckOther solid neoplasmSarcomaThoracic

Pleuropulmonary blastoma, Nasopharyngeal Carcinoma, Adrenal Cortex Neoplasms, Melanoma, Mesothelioma, Pancreatic Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors

Clinical Trials

LUPARPED

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Long-Term Longitudinal QoL in Patients Undergoing EEA

PARTNER